drugset / Trial / NCT04015596

Trial of Naproxen Sodium for the Treatment of OCD in Children With PANDAS

NCT04015596

Phase 4 Terminated 2 enrolled Massachusetts General Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This project aims to rigorously evaluate a potential treatment for inflammation-related Obsessive-Compulsive Disorder (OCD) symptoms in children. To accomplish this goal, the investigators will conduct a double-blind, randomized, placebo-controlled trial of Naproxen Sodium, a nonsteroidal anti-inflammatory drug (NSAID) in participants diagnosed with Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal infections (PANDAS). This research fills a gap in the empirical evidence base for the treatment of PANDAS, and will add to a growing literature of empirically-derived practices for PANDAS.

Timeline

Start
2020-10-20
Primary completion
2025-04-30
Completion
2025-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Naproxen Small molecule 10 mg/kg Oral